Randomized Phase II Trial of the Sequences of Anthracyline and Taxane in Locally Advanced Breast Cancer
Anthracylines and taxanes are the most active chemotherapy agents in the treatment of breast
cancer. The usual sequence of an anthracycline followed by a taxane is due to the timing of
their discovery and introduction in the treatment armamentarium. More recent evidence
suggests that there is pre clinical as well as clinical rational for the reverse sequence.
The neoadjuvant approach allows quick evaluation of these different treatment strategies. At
the same time, the study will collect tissue biopsies and blood at different time points in
order to evaluate predictive biomarkers.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Pathological complete response
Jose Bines, MD
Brazil: Ministry of Health